This research is not only relevant to ovarian cancer, but also applicable to other tumor types, such as breast and colon cancers, in which peritoneal metastasis is an important pathological process, indicating that sLex-P-selectin could become promising therapeutic targets. This evidence concerns the gene SELP and colonic neoplasm.